OPKO Health (NASDAQ:OPK) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. assumed coverage on shares of OPKO Health (NASDAQ:OPK) in a research note released on Thursday morning, Marketbeat reports. The firm issued a neutral rating on the biotechnology company’s stock.

OPK has been the subject of a number of other reports. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. Zacks Research upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Wall Street Zen raised shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 1st. Finally, Jefferies Financial Group reaffirmed a “hold” rating and set a $1.60 target price (down from $2.00) on shares of OPKO Health in a research note on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, OPKO Health presently has a consensus rating of “Hold” and an average price target of $2.28.

OPKO Health Price Performance

Shares of OPK opened at $1.30 on Thursday. The firm has a 50-day simple moving average of $1.44 and a two-hundred day simple moving average of $1.37. The stock has a market cap of $998.01 million, a PE ratio of -5.20 and a beta of 1.50. OPKO Health has a 1-year low of $1.11 and a 1-year high of $2.04. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.41 and a quick ratio of 3.02.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.62%. The firm had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. During the same period in the prior year, the business posted $0.03 EPS. The business’s revenue for the quarter was down 12.6% compared to the same quarter last year. As a group, analysts forecast that OPKO Health will post -0.25 EPS for the current year.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 580,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 19th. The shares were purchased at an average cost of $1.31 per share, for a total transaction of $759,800.00. Following the completion of the purchase, the chief executive officer owned 216,126,448 shares of the company’s stock, valued at approximately $283,125,646.88. This represents a 0.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 1,263,300 shares of company stock worth $1,650,091 over the last three months. Insiders own 49.69% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

A number of large investors have recently modified their holdings of the company. Oak Thistle LLC acquired a new stake in shares of OPKO Health in the 1st quarter valued at $26,000. Caprock Group LLC acquired a new position in shares of OPKO Health during the third quarter worth $26,000. GM Advisory Group LLC purchased a new position in OPKO Health in the first quarter valued at $33,000. Savant Capital LLC purchased a new position in OPKO Health in the third quarter valued at $33,000. Finally, Cerity Partners LLC acquired a new stake in OPKO Health in the first quarter valued at $36,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.